177 related articles for article (PubMed ID: 36018224)
21. Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
Elalfy MS; Hamdy M; Adly A; Ebeid FSE; Temin NT; Rozova A; Lee D; Fradette C; Tricta F
Am J Hematol; 2023 Sep; 98(9):1415-1424. PubMed ID: 37401738
[TBL] [Abstract][Full Text] [Related]
22. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
23. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Chuansumrit A; Songdej D; Sirachainan N; Wongwerawattanakoon P; Kadegasem P; Sasanakul W
Paediatr Int Child Health; 2016 Aug; 36(3):209-13. PubMed ID: 26052612
[TBL] [Abstract][Full Text] [Related]
24. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Sridharan K; Sivaramakrishnan G
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
[TBL] [Abstract][Full Text] [Related]
26. Iron Overload in Patients With Heavily Transfused Sickle Cell Disease-Correlation of Serum Ferritin With Cardiac T2
Alkindi S; Panjwani V; Al-Rahbi S; Al-Saidi K; Pathare AV
Front Med (Lausanne); 2021; 8():731102. PubMed ID: 34760898
[TBL] [Abstract][Full Text] [Related]
27. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
28. The Long-Term Efficacy of Deferiprone in Thalassemia Patients With Iron Overload: Real-World Data from the Registry Database.
Kittipoom T; Tantiworawit A; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Fanhchaksai K; Charoenkwan P
Hemoglobin; 2022 Mar; 46(2):75-80. PubMed ID: 35982534
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
[TBL] [Abstract][Full Text] [Related]
30. Hepatic and Cardiac Iron-load in Children on Long-term Chelation with Deferiprone for Thalassemia Major.
Totadri S; Bansal D; Trehan A; Khadwal A; Bhatia A; Sodhi KS; Bhatia P; Jain R; Das R; Khandelwal N
Indian Pediatr; 2018 Jul; 55(7):573-575. PubMed ID: 30129538
[TBL] [Abstract][Full Text] [Related]
31. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
Olivieri NF; Sabouhanian A; Gallie BL
PLoS One; 2019; 14(2):e0211942. PubMed ID: 30811439
[TBL] [Abstract][Full Text] [Related]
32. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Porter JB; El-Alfy M; Viprakasit V; Giraudier S; Chan LL; Lai Y; El-Ali A; Han J; Cappellini MD
Eur J Haematol; 2016 Jan; 96(1):19-26. PubMed ID: 25691036
[TBL] [Abstract][Full Text] [Related]
33. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
34. Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Blood Adv; 2023 Jun; 7(12):2925. PubMed ID: 37368454
[No Abstract] [Full Text] [Related]
35. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
36. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
37. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
38. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Adamkiewicz TV; Abboud MR; Paley C; Olivieri N; Kirby-Allen M; Vichinsky E; Casella JF; Alvarez OA; Barredo JC; Lee MT; Iyer RV; Kutlar A; McKie KM; McKie V; Odo N; Gee B; Kwiatkowski JL; Woods GM; Coates T; Wang W; Adams RJ
Blood; 2009 Nov; 114(21):4632-8. PubMed ID: 19721013
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
Elalfy MS; Adly A; Awad H; Tarif Salam M; Berdoukas V; Tricta F
Am J Hematol; 2018 Feb; 93(2):262-268. PubMed ID: 29119631
[TBL] [Abstract][Full Text] [Related]
40. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Schell LK; Rücker G; Motschall E; Fleeman N; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2014 Jun; 5(5):CD007477. PubMed ID: 24893174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
